Molecular mechanisms of resistance to HER2-targeted therapy

被引：2
|
作者：
Esteva, F. J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BREAST CANCER RESEARCH | 2009年 / 11卷
关键词：
HUMAN-BREAST-CANCER; TRASTUZUMAB;
D O I：
10.1186/bcr2283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S10 / S10
页数：1
相关论文
共 50 条
  • [41] Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
    Creedon, Helen
    Gomez-Cuadrado, Laura
    Tarnauskaite, Zygimante
    Balla, Jozef
    Canel, Marta
    MacLeod, Kenneth G.
    Serrels, Bryan
    Fraser, Craig
    Unciti-Broceta, Asier
    Tracey, Natasha
    Le Bihan, Thierry
    Klinowska, Teresa
    Sims, Andrew H.
    Byron, Adam
    Brunton, Valerie G.
    ONCOTARGET, 2016, 7 (10) : 11539 - 11552
  • [42] HER2-targeted therapy: an emerging strategy in advanced colorectal cancer
    La Salvia, Anna
    Lopez-Gomez, Victoria
    Garcia-Carbonero, Rocio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (01) : 29 - 38
  • [43] HER2-targeted antibody drug conjugates for ovarian cancer therapy
    Jiang, Jing
    Dong, Lihou
    Wang, Lei
    Wang, Ling
    Zhang, Jing
    Chen, Fang
    Zhang, Xiuli
    Huang, Min
    Li, Shenjun
    Ma, Weiwei
    Xu, Qiaoyu
    Huang, Changjiang
    Fang, Jianmin
    Wang, Chunhua
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 93 : 274 - 286
  • [44] Resistance to HER2-targeted therapies: a potential role for FOXM1
    Peake, Bridgette F.
    Nahta, Rita
    BREAST CANCER MANAGEMENT, 2014, 3 (05) : 423 - 431
  • [45] Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
    Sharial, M. S. N. Mohd
    Crown, J.
    Hennessy, B. T.
    ANNALS OF ONCOLOGY, 2012, 23 (12) : 3007 - 3016
  • [46] Cardiotoxicity of novel HER2-targeted therapies
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (08) : 1015 - 1024
  • [47] Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
    Fernandez-Nogueira, Patricia
    Mancino, Mario
    Fuster, Gemma
    Lopez-Plana, Anna
    Jauregui, Patricia
    Almendro, Vanesa
    Enreig, Estel
    Menendez, Silvia
    Rojo, Federico
    Noguera-Castells, Aleix
    Bill, Anke
    Gaither, L. Alex
    Serrano, Laia
    Recalde-Percaz, Leire
    Moragas, Nuria
    Alonso, Raul
    Ametller, Elisabet
    Rovira, Ana
    Lluch, Ana
    Albanell, Joan
    Gascon, Pere
    Bragado, Paloma
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1432 - 1448
  • [48] Truncated HER2: implications for HER2-targeted therapeutics
    Zagozdzon, Radoslaw
    Gallagher, William M.
    Crown, John
    DRUG DISCOVERY TODAY, 2011, 16 (17-18) : 810 - 816
  • [49] Loss of HER2 after HER2-targeted treatment
    Ignatov, Tanja
    Gorbunow, Franceska
    Eggemann, Holm
    Ortmann, Olaf
    Ignatov, Atanas
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (02) : 401 - 408
  • [50] TNFα induces multiresistance to HER2-targeted TNFα induces multiresistance to HER2-targeted therapies in HER2-positive breast cancer
    Mercogliano, Maria F.
    De Martino, Mara
    Bruni, Sofia
    Venturutti, Leandro
    Rivas, Martin
    Amasino, Matias
    Proietti, Cecilia J.
    Elizalde, Patricia V.
    Schillaci, Roxana
    CANCER RESEARCH, 2017, 77
12345